Antibody Information
General Information of This Antibody
| Antibody ID | ANI0XZCCF |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Nimotuzumab |
|||||
| Brand Name | THERACIM |
|||||
| Organization | Center For Molecular Immunology; Eurofarma Laboratrios SA; CIMYM Biosciences, Inc. |
|||||
| Indication | Head and neck cancer; Gastric cancer; Pancreatic cancer |
|||||
| Approval Date | Apr. 2005 |
|||||
| Synonyms |
hR3; Theraloc; HR3; Nimotuzumab; NIMOTUZUMAB; OSAG 101; THERACIM-HR3; THERALOC; THERALOC THERACIM
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Epidermal growth factor receptor (EGFR) |
Antigen Info | ||||
| ChEMBI ID | ||||||
| PDB ID | ||||||
| DrugBank ID | ||||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
QVQLQQSGAEVKKPGSSVKVSCKASGYTFTNYYIYWVRQAPGQGLEWIGGINPTSGGSNF
NEKFKTRVTITVDESTNTAYMELSSLRSEDTAFYFCARQGLWFDSDGRGFDFWGQGSTVT VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain Varible Domain |
QVQLQQSGAEVKKPGSSVKVSCKASGYTFTNYYIYWVRQAPGQGLEWIGGINPTSGGSNF
NEKFKTRVTITVDESTNTAYMELSSLRSEDTAFYFCARQGLWFDSDGRGFDFWGQGSTVT VSS Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 1 |
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 2 |
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 3 |
GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain Hinge Region |
EPKSCDKTHTCPPCP
Click to Show/Hide
|
|||||
| Heavy Chain CDR 1 |
GYTFTNYY
Click to Show/Hide
|
|||||
| Heavy Chain CDR 2 |
INPTSGGS
Click to Show/Hide
|
|||||
| Heavy Chain CDR 3 |
ARQGLWFDSDGRGFDF
Click to Show/Hide
|
|||||
| Light Chain Sequence |
DIQMTQSPSSLSASVGDRVTITCRSSQNIVHSNGNTYLDWYQQTPGKAPKLLIYKVSNRF
SGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFQYSHVPWTFGQGTKLQITREVAAPSV FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain Varible Domain |
DIQMTQSPSSLSASVGDRVTITCRSSQNIVHSNGNTYLDWYQQTPGKAPKLLIYKVSNRF
SGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFQYSHVPWTFGQGTKLQI Click to Show/Hide
|
|||||
| Light Chain Constant Domain |
TREVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain CDR 1 |
QNIVHSNGNTY
Click to Show/Hide
|
|||||
| Light Chain CDR 2 |
KVS
Click to Show/Hide
|
|||||
| Light Chain CDR 3 |
FQYSHVPWT
Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
CN112341521B+ADC-5 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC54) |
20.44 ug/mL
|
|||
| Method Description |
Add the antibody-coupled drug product C or nimotuzumab with a specified concentration to the cells, incubate for 3 days, and then add 40uL of Promega CellTiter-Glo reagent (Promega catalog number G968B). Subsequently, the chemiluminescence reading from CellTiter-Glo reagent was read to determine IC50 (54%% inhibitory concentration).
|
||||
| In Vitro Model | Lung adenocarcinoma | HCC-827 cells | CVCL_2063 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC53) |
1181 ug/mL
|
|||
| Method Description |
Add the antibody-coupled drug product C or nimotuzumab with a specified concentration to the cells, incubate for 3 days, and then add 40uL of Promega CellTiter-Glo reagent (Promega catalog number G968B). Subsequently, the chemiluminescence reading from CellTiter-Glo reagent was read to determine IC50 (53%% inhibitory concentration).
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1975 cells | CVCL_1511 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC52) |
64.44 ug/mL
|
|||
| Method Description |
Add the antibody-coupled drug product C or nimotuzumab with a specified concentration to the cells, incubate for 3 days, and then add 40uL of Promega CellTiter-Glo reagent (Promega catalog number G968B). Subsequently, the chemiluminescence reading from CellTiter-Glo reagent was read to determine IC50 (52%% inhibitory concentration).
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC51) |
25.96 ug/mL
|
|||
| Method Description |
Add the antibody-coupled drug product C or nimotuzumab with a specified concentration to the cells, incubate for 3 days, and then add 40uL of Promega CellTiter-Glo reagent (Promega catalog number G968B). Subsequently, the chemiluminescence reading from CellTiter-Glo reagent was read to determine IC50 (51%% inhibitory concentration).
|
||||
| In Vitro Model | Squamous cell carcinoma of the oral tongue, Tongue squamous cell carcinoma | CAL33 cells | CVCL_1108 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1.69 ug/mL
|
|||
| Method Description |
Add the antibody-coupled drug product C or nimotuzumab with a specified concentration to the cells, incubate for 3 days, and then add 40uL of Promega CellTiter-Glo reagent (Promega catalog number G968B). Subsequently, the chemiluminescence reading from CellTiter-Glo reagent was read to determine IC50 (50%% inhibitory concentration).
|
||||
| In Vitro Model | Hypopharyngeal squamous cell carcinoma | FaDu cells | CVCL_1218 | ||
US12144865B2 1i [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50)Human PBMC |
0.491 nM
|
Positive EGFR expression (EGFR+++/++) | ||
| Method Description |
Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
|
||||
| In Vitro Model | Lung mucoepidermoid carcinoma | NCI-H292 cells | CVCL_0455 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50)Human PBMC |
3.84 nM
|
Positive EGFR expression (EGFR+++/++) | ||
| Method Description |
Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
|
||||
| In Vitro Model | Liver and intrahepatic bile duct epithelial neoplasm | SK-HEP-1 cells | CVCL_0525 | ||
References